Insmed Incorporated
INSM
주식 순위
#1110
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
주가
$95.88
마지막 동기화: 2026-10-20
시가총액
$20.94B
변동 (1일)
0.61%
변동 (1년)
-42.00%
국가
US
거래 Insmed Incorporated (INSM)
카테고리
Healthcare
Insmed Incorporated (INSM)의 매출
Jun 2026 기준 매출 TTM: $1.14B
Insmed Incorporated의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.14B입니다. 2023년에 회사는 $305.21M의 수익을 올렸으며 이는 2022년의 $245.36M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Insmed Incorporated의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.14B | 212.79% |
| 2024 | $363.71M | 19.17% |
| 2023 | $305.21M | 24.39% |
| 2022 | $245.36M | 30.19% |
| 2021 | $188.46M | 14.63% |
| 2020 | $164.41M | 20.48% |
| 2019 | $136.47M | 1,287.56% |
| 2018 | $9.84M | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | $11.50M | 0.00% |
| 2013 | $11.50M | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | $4.42M | -36.18% |
| 2010 | $6.92M | -33.28% |
| 2009 | $10.37M | -11.33% |
| 2008 | $11.70M | 55.39% |
| 2007 | $7.53M | 659.74% |
| 2006 | $991.00K | 656.49% |
| 2005 | $131.00K | -4.38% |
| 2004 | $137.00K | -8.67% |
| 2003 | $150.00K | -92.33% |
| 2002 | $1.96M | 560.47% |
| 2001 | $296.00K | 393.33% |
| 2000 | $60.00K | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 1,009.70% |
US
|
|
| $2.23B | 95.84% |
US
|
|
| $15.74B | 1,283.95% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 429.28% |
NL
|
